Acute exacerbation of chronic obstructive pulmonary
Conditions
Interventions
Control group:Nebulized saline
Drug group:Atomized ambroxol hydrochloride
Multi-function device group:multi-function device excise
Combination group:Atomized ambroxol hydrochloride and multi-function device excise
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
51 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria can be enrolled: 1) Meet the lower respiratory tract infections (such as acute exacerbation of chronic bronchitis, pneumonia, acute exacerbation of chronic obstructive pulmonary disease, bronchiectasis without hemoptysis, etc.) clinical diagnostic criteria; 2) Must have symptoms of adhesion (sputum trait score = 2 points), symptoms of cough difficulty (cough difficulty score = 2 points), 24h sputum = 10ml and other clinical symptoms; 3) Hospitalized patients; 4) Aged 18 to 80 years, gender is not limited; 5) The subject has fully understood and voluntarily signed the informed consent form; 6) The Zheng's multi-function device can be used correctly.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will not be allowed to participate in the study: 1) Those who are known to be allergic to the test drug ingredients and pharmaceutical excipients; 2) Only patients with upper respiratory tract infection; 3) Patients with bronchiectasis with hemoptysis, pneumothorax, severe pulmonary hypertension, severe pulmonary infection requiring ICU therapy, active tuberculosis, tuberculous pleurisy, and severe respiratory failure requiring 24 hours of ventilator-assisted therapy; 4) Patients who are unable to cooperate with nebulization therapy or physical drainage, can not correctly use Zheng's respiratory valve, and chest imaging indicates the presence of pulmonary bullae with a diameter of more than 8cm; 5) Take Chinese medicine and western medicine, such as antitussive and expectorant drugs, which improve the symptoms of lower respiratory tract infections, except for the research drug, within 1 day before the first dose (24h). 6) Previously or currently combined with any of the following major diseases: a history of cerebrovascular accidents within the last 3 months, such as ischemic stroke and hemorrhagic stroke; unstable angina, myocardial infarction within the last 3 months, History of heart failure; inability to cough up sputum; large aneurysm or dissection aneurysm; percutaneous transluminal coronary angioplasty or cardiac surgery; severe liver disease or liver dysfunction; severe nephropathy; severe hematopoiesis Systemic primary disease or agranulocytosis patients. 7) Before entering the group, any laboratory inspection indicators meet the following criteria: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 1.5 times the upper limit of normal; serum creatinine value (Cr) > 1.5 times the upper limit of normal; 8) Other situations that are not suitable for participation in the study: Those who have participated in or are participating in other researchers one month before screening; have a history of drug use, alcohol or drug abuse; those who have serious neurological and psychiatric disorders who cannot fully understand and cooperate; pregnant women who are pregnant, breastfeeding, and planning to become pregnant Or male patients; unable to comply with the requirements of the study protocol; the investigator believes that there are other circumstances that are not suitable for clinical trials. 9) Patients who are considered unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of sputum; | — |
Countries
China
Contacts
Public ContactZheng Zeguang
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed